English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 4/5 criteria met. Data as of 04/11/2026.
- ❌ Price trend failed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -30.00%
Price change 2019 → 2020: -14.05%
Price change 2020 → 2021: 18.56%
Price change 2021 → 2022: 24.84%
Price change 2022 → 2023: 7.36%
Price change 2023 → 2024: 2.59%
Price change 2024 → 2025: 7.50%
Price change 2025 → 2026: 28.74%
Price change 2026 (year to date): 31.96%
Financial growth
Revenue CAGR (8 years): 6.61%
Earnings CAGR (8 years): 1.90%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.20
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 24.72
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 11.39% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="IPN.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Ipsen S.A. | 25.4 | 0.20 | +7.9 % | 🔒 |
| bioMérieux S.A. | 22.8 | 0.11 | +7.6 % | – |
| Viatris Inc. | 7.5 | 1.00 | +6.6 % | – |
| BioNTech SE | – | 0.01 | +60.8 % | – |
| Sartorius Stedim Biotech S.A. | 50.4 | 0.64 | +13.7 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Ipsen S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 3.0 bn | 611 m | 20.4 % | n/a |
| 2021 | 3.1 bn | 721 m | 23.5 % | +2.3 % |
| 2022 | 3.5 bn | 723 m | 20.6 % | +14.8 % |
| 2023 | 3.7 bn | 718 m | 19.5 % | +4.8 % |
| 2024 | 4.0 bn | 386 m | 9.7 % | +8.1 % |
| 2025 | 4.1 bn | 496 m | 12.1 % | +2.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Ipsen S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 815 m | 1.2 bn | 528 m | 679 m | 1.5 bn |
| Total Debt | 787 m | 772 m | 463 m | 427 m | 867 m |
| Net Debt | -28.1 m | -398 m | -65.5 m | -251 m | -658 m |
| Equity | 2.7 bn | 3.3 bn | 3.8 bn | 4.2 bn | 4.3 bn |
| Total assets | 5.0 bn | 5.6 bn | 6.3 bn | 6.4 bn | 6.9 bn |
| Operating cash flow | 872 m | 953 m | 866 m | 916 m | 1.1 bn |
| Investments (capex) | 418 m | 253 m | 116 m | 173 m | 329 m |
| Free cash-flow | 454 m | 700 m | 750 m | 133 m | 1.0 bn |
| Share buybacks | 36.7 m | 11.3 m | 39.5 m | 36.5 m | 67.7 m |
| Dividends paid | 82.9 m | 99.3 m | 99.6 m | 99.6 m | 116 m |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Ipsen S.A. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Ipsen S.A. | 14.6 bn | 25.4 | 12.1 % |
| Innate Pharma S.A. IPH.PA | 132 m | n/a | -1,764.5 % |
| OSE Immunotherapeutics S.A. OSE.PA | 51.3 m | n/a | -1,439.5 % |
| Abivax S.A. ABVX.PA | 7.7 bn | n/a | 0.0 % |
| Transgene S.A. TNG.PA | 226 m | n/a | -7,658.0 % |
| Valerio Therapeutics S.A. ALVIO.PA | 257 m | n/a | -190.4 % |
| TME Pharma N.V. ALTME.PA | 13.2 m | n/a | 0.0 % |
| Cellectis S.A. ALCLS.PA | 84.0 m | n/a | -92.7 % |
| Nanobiotix S.A. NANO.PA | 1.6 bn | n/a | -80.8 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Ipsen S.A. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 4.5 bn | 1.2 bn | 14.42 (13.99 / 14.99) | 10.9 | 6 |
| 2027 | 4.7 bn | 1.2 bn | 13.55 (12.39 / 15.45) | 11.6 | 11 |
| 2028 | 4.8 bn | 1.2 bn | 13.16 (10.34 / 16.62) | 12.0 | 10 |
Amounts in EUR, the reporting currency.
Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Ipsen S.A.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 03/06/2026 | 1.60 EUR | 05/06/2026 |
| 04/06/2025 | 1.40 EUR | 06/06/2025 |
| 30/05/2024 | 1.20 EUR | 03/06/2024 |
| 02/06/2023 | 1.20 EUR | 06/06/2023 |
| 31/05/2022 | 1.20 EUR | 02/06/2022 |
| 31/05/2021 | 1.00 EUR | 02/06/2021 |
| 03/06/2020 | 1.00 EUR | 05/06/2020 |
| 31/05/2019 | 1.00 EUR | 04/06/2019 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 30/07/2026 | 4.87 | 6.49 | -25.0 % |
| 12/02/2026 | 6.02 | 5.53 | +8.9 % |
| 31/07/2025 | 7.33 | 6.49 | +12.9 % |
| 16/04/2025 | 6.02 | 5.53 | +8.9 % |
| 22/10/2024 | 6.07 | 5.57 | +9.0 % |
| 24/04/2024 | 5.38 | 5.36 | +0.4 % |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Ipsen S.A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Ipsen S.A.
What is the Ipsen S.A. share price?
Latest recorded price: 158.70 EUR on 06/11/2026, for a market cap of 14.6 bn USD.
What is the revenue of Ipsen S.A.?
4.1 bn USD for fiscal year 2025, with net income of 496 m USD (net margin 12.1 %).
Does Ipsen S.A. pay a dividend?
Yes. Latest dividend: 1.60 EUR per share, ex-dividend on 03/06/2026. Over 12 months: 1.60 EUR. Yield on the latest known price: 1.2 %.
When does Ipsen S.A. report its next earnings?
The next release is expected on 11/02/2027. EPS expected by analysts: 7.88.
What do analysts say about Ipsen S.A.?
Out of 15 analysts: 6 buy or strong buy, 6 hold, 3 sell or strong sell.
What is the P/E ratio of Ipsen S.A.?
Trailing 12-month P/E of 25.6.
Is Ipsen S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0010259150) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Ipsen S.A. have?
5,358 full-time employees according to the latest published profile.
Who runs Ipsen S.A.?
David Loew is the company's chief executive.